• Project: PET-Diagnostics in collaboration with PharmIdea

    Project: PET-Diagnostics in collaboration with PharmIdea

    TBD Pharmatech worked on a PET-diagnostics project together with Latvian partner SIA PharmIdea from 2017 until 2019. The main objective of the Project was to develop a PET-product used in Positron emission tomography-computer tomography (PET-CT) for cancer, Alzheimer or Parkinson diagnostics. The outcome of the Project was final dosage form of the PET-product with all the documentation package, necessary for its implementation in nuclear medicine centers and hospitals. After the first Product has been developed and marketed, TBD and PharmIdea plan to continue the cooperation and develop the next PET-diagnostics and other products for oncology studies, studies of Alzheimer and

    Read more
  • LIOS and TBD Pharmatech join forces

    LIOS and TBD Pharmatech join forces

    On 21st February 2023, the Latvian Institute of Organic Synthesis (LIOS) and TBD Pharmatech signed the Memorandum of Understanding to strengthen the drug manufacturing performance of the Baltic region. The alliance will perform joint projects for manufacturing technology development and the production of active pharmaceutical ingredients (APIs). It will also support and promote new trends in API manufacturing such as the introduction of green technologies and advanced safety aspects. “Memorandum of understanding with TBD Pharmatech is a very important step forward for LIOS to become an integral part of the API technologies development ecosystem by linking our research capacities to

    Read more
  • Project: A breakthrough technology for dental root canal treatments to save teeth (EndoSolution)

    Project: A breakthrough technology for dental root canal treatments to save teeth (EndoSolution)

    The aim of this collaboration project is to develop a breakthrough technology in root canal treatment, specifically entirely novel endodontic filling material (Endofill) and a device to solidify the injectable material within the root canal (Fibercure). The product line is the first of its kind in the world and will completely revolutionize root canal treatments enabling any dentist to perform these treatments in a fast, simple and noninvasive manner and with a significantly higher treatment efficiency and success rate. The project is led by Lumendo AG together with three key partners: TBD-Biodiscovery (Tartu, Estonia) and Studio Mango (Breda, The Netherlands)

    Read more